NSTK · 01.2026Independent supplement reference
NutriStack
Edition 1.0Updated August 1, 2026

Supplement × Supplement·Evidence index

Probiotics and Saccharomyces Boulardii: what the published research says

PubMed indexes 3 records that name Probiotics and Saccharomyces Boulardii together, either in the title or in an interaction, co-administration, or pharmacokinetic context. 2 further sources came from NutriStack’s own review rather than from that query, and are labelled as such. Each one is listed below with its study design and, where the abstract states one, the authors’ own conclusion, quoted and linked. This page reports that literature. It does not tell you whether to combine them.

Read this first

An evidence index, not guidance.

Every statement below is attributed to a named, dated, linked source.

This page lists published research relevant to Probiotics and Saccharomyces Boulardii. It deliberately does not state whether the combination is safe, whether it interacts, in which direction, at what dose, or how far apart to take them.

The research

5 studies naming Probiotics and Saccharomyces Boulardii.

Hand-reviewed sources first, then papers naming both substances in the title, then human trials and systematic reviews.

Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis.

JAMA · 2012 · PMID 22570464

Meta-AnalysisResearch Support, N.I.H., ExtramuralResearch Support, U.S. Gov't, Non-P.H.S.Systematic Review

“The pooled evidence suggests that probiotics are associated with a reduction in AAD. More research is needed to determine which probiotics are associated with the greatest efficacy and for which patients receiving which specific antibiotics.”

Hempel et al. · Authors' conclusion

Selected by hand during source review for Probiotics and Saccharomyces Boulardii, rather than by the automated PubMed query. It covers one side of the pair; it is listed as background the reviewer relied on, not as a study of the combination.

Systematic review and meta-analysis of Saccharomyces boulardii in adult patients.

World journal of gastroenterology · 2010 · PMID 20458757

EditorialMeta-AnalysisSystematic ReviewHuman subjects

“The use of S. boulardii as a therapeutic probiotic is evidence-based for both efficacy and safety for several types of diarrhea.”

McFarland · From the abstract

Selected by hand during source review for Probiotics and Saccharomyces Boulardii, rather than by the automated PubMed query. It covers one side of the pair; it is listed as background the reviewer relied on, not as a study of the combination.

Saccharomyces boulardii and Bifidobacterium co-treatment for antibiotic associated diarrhea in pediatrics: a multicenter efficacy and safety study.

Frontiers in cellular and infection microbiology · 2025 · PMID 40630636

Multicenter StudyHuman subjects

“Any type of antibiotic treatment cause diarrhea in infants and young children. Probiotics especially Saccharomyces boulardii co-treatments with any type of antibiotic treatment, significantly reduce incidences of diarrhea in infants and young children with manageable adverse effects.”

Liu et al. · Authors' conclusion

Names both Probiotics and Saccharomyces Boulardii in its title.

Can the Evidence-Based Use of Probiotics (Notably Saccharomyces boulardii CNCM I-745 and Lactobacillus rhamnosus GG) Mitigate the Clinical Effects of Antibiotic-Associated Dysbiosis?

Advances in therapy · 2024 · PMID 38286962

Human subjects

“A robust body of evidence from clinical trials and meta-analyses shows that the timely administration of an adequately dosed probiotic (upon initiation of antibiotic treatment or within 48 h) can help to prevent or resolve the consequences of antibiotic-associated dysbiosis (such as diarrhoea) and promote the resilience of the gut microbiota and a return to the pre-antibiotic state.”

Waitzberg et al. · From the abstract

Names both Probiotics and Saccharomyces Boulardii in its title.

Efficacy and safety of Saccharomyces boulardii as adjunct therapy with Vancomycin in treating Clostridioides difficile infection: A randomized controlled trial.

Scientific reports · 2025 · PMID 40457042

Randomized Controlled Trial

“In conclusion, adding S. boulardii to vancomycin reduced CDI recurrence without affecting functional recovery or increasing adverse events.”

Chitapanarux et al. · From the abstract

Names Probiotics and Saccharomyces Boulardii together in an interaction, co-administration, or pharmacokinetic context.

Limitations

What this evidence cannot tell you.

Search-based evidence indexes have real limits, and it is worth being explicit about them:

NutriStack

Track what you actually take.

NutriStack is a free iPhone app for organising a supplement routine: what you take, when, and what the published record says about it. Its exploratory interaction checker covers Probiotics, Saccharomyces Boulardii, and several hundred other substances.

The checker is a research and organisation tool, not a clinical decision aid, and its per-pair assessments are excluded from search until they pass claim-level review.

NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.